Biologic markers determine both the risk and the timing of recurrence in breast cancer. - Wikidata - wikimedia - TriplyDB

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

http://www.wikidata.org/entity/Q35073921

about

Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time?Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients Markers for the identification of late breast cancer recurrence.Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).Breast Cancer beyond the Age of Mutation.Adjuvant endocrine therapy in premenopausal women with breast cancer.Mathematical models of breast and ovarian cancers.Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncolog Factors predicting late recurrence for estrogen receptor-positive breast cancer From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.The recurrence frequency of breast cancer and its prognostic factors in Iranian patients.An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.Translating metastasis-related biomarkers to the clinic--progress and pitfalls.The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer.Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors.Patterns of recurrence and treatment in male breast cancer: A clue to prognosis?A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.Integrated miRNA and mRNA profiling of tumor-educated macrophages identifies prognostic subgroups in estrogen receptor-positive breast cancer.The WISDOM Study: breaking the deadlock in the breast cancer screening debate.Significance of ERα, HER2, and CAV1 expression and molecular subtype classification to canine mammary gland tumor.Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement.Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care.Cost Effectiveness of Gene Expression Profile Testing in Community Practice.Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.Late distant recurrence of breast carcinoma and metastasis to the main bronchus and choroid: A case report.Optimal management of luminal breast cancer: how much endocrine therapy is long enough?Breast cancer screening: the questions answered

P2860

Q30768230-ED85AAED-9728-4FAA-A6F5-A8D1D91B813C Q33954572-CC3026BB-D728-4B97-9FF4-E303856196DB Q34109691-80925FF7-8339-402D-B411-832475FD926E Q35000874-D0ED42E6-2D6A-4B15-AC47-2D6A269E41DD Q35008290-46BEBE08-18F7-4234-A160-98471A15FE59 Q35018949-1BE851CB-1352-46EE-BAB3-31FE984118A8 Q35559368-5EFFF196-4493-43C4-9DE8-EED3469B19D0 Q35904572-042DDE08-3946-487B-9DC0-C7BD70A6A3D9 Q36880525-F3AA7D28-8D43-44C3-9107-ED80272B1E99 Q36976772-BC2B0322-924B-4820-8D7A-24B4043450AE Q37014152-7C7CEB49-6B28-4430-A6B7-B3A38C0FDC0B Q37169337-B3F9E452-0B13-4281-97DF-7DEC390E9B4C Q37209554-6459B0B8-481A-49F6-8883-CA64D7523779 Q37214217-2494B0EA-4EB6-47BC-A92A-E8E2D0B3EDAB Q37385272-A1B819DD-4920-424C-97E7-F9BD1C54790B Q37668443-CB0937E2-6557-4276-A446-B6E0F5AEF35B Q37689702-501B8654-ECE7-421A-8D96-FEF5D359CC72 Q37723914-0A75C072-165E-4B1C-B1C0-378A656DD8A9 Q38079125-ABCB364E-CB08-4FFA-8AA3-6EC3FCA17EF7 Q38295108-4F7A24DE-EF36-4500-A09D-AAE47AB570FF Q39592988-3B15E4DF-F59C-441C-A080-638891A51D69 Q40710424-76E2B61E-7CD3-4583-AFAC-96B779C7CAEE Q41134433-DCA6B7FA-31C5-4817-90E2-1B2503072A5C Q41135798-D476B5BD-22B5-457E-A87E-AD4CBEF976B6 Q41701590-9C71418E-846A-4968-B4C4-A548191A81EB Q42457894-0C384BF6-AC17-45D7-AAA3-33DE7EC6DDBD Q43128167-EF43E1C2-1A67-4A64-9CDD-8B990291310A Q45982151-0A5DDBFF-38DF-4C66-BC13-E29EC15761BE Q46033349-B80DF608-A1A6-4C0D-9A27-B203E2FA2448 Q47198620-281E0F7E-8E9B-4CAF-BD8A-BB6F6EB44D77 Q51772667-FB47C9C6-737D-48EC-984E-7DFFD87A5B0F Q53058836-4FD8A2D8-07D7-4240-AD94-A9BA9D3A5D2E Q55280867-1DED9DF4-8F2F-43A9-ACF5-D05EACA1F3CC Q55424072-9F613DC0-061E-45EE-9278-8165ACE3B4E3 Q57133196-FBEEBAED-ED08-402A-BB69-7E1E84041EC6

P2860

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

http://www.wikidata.org/entity/Q35073921

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

@ast

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

@en

type

label

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

@ast

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

@en

prefLabel

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

@ast

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

@en

P1433

Q35073921-0BF354FA-2CBB-4736-A75F-204C373A621C

P1476

Q35073921-6E04C5BB-F4B6-45EC-8526-7FE009623E9A

P2093

Q35073921-19E13949-7529-44F3-B6B9-EC5D208E610B

Q35073921-39C191D6-97CF-45ED-BB3F-67E240DB4706

Q35073921-70A6AAC9-8733-4410-83CA-A8BFBDAF4812

Q35073921-73BA5B87-03CC-46E6-92EC-205C375DF186

Q35073921-77A91287-C69E-44B5-A723-3362CC0D7179

Q35073921-880278D3-04EC-40DF-896A-F595DD58BDB1

Q35073921-8B187CBA-B67C-4E8E-A4C2-E32C0E9A5330

Q35073921-941B1541-70E2-47F7-8894-52E9F1A9CABC

Q35073921-95A3BD8D-14AE-409C-AEE8-12BDB6960A84

Q35073921-9B4E54A9-1642-41AB-A90A-1AE2312EA725

P2860

Q35073921-04B09E00-E894-4030-9B94-F068DD81B9E1

Q35073921-13ED8037-7D86-4043-BAAF-1C62B97BE9FA

Q35073921-2C892611-FB66-40FA-92B1-01F6E557B1AF

Q35073921-379EC4F3-DECB-4698-BAF9-CAD7CA10D42C

Q35073921-3818A489-D167-4FEE-AE53-170046527620

Q35073921-39256567-A497-48A3-A3A3-BA9795B26222

Q35073921-3D1E780E-3AE3-40BC-967B-2BDD680CD950

Q35073921-3E0AA50A-1B41-4C63-859A-856310BA3FA5

Q35073921-41F76B39-2FD9-4DAA-AD1F-6528710EE853

Q35073921-42B9C088-308D-46BD-9962-190CC9A54C22

P2888

Q35073921-0B3C1E58-C7DB-4344-822A-E4F5ECC65E9F

P304

Q35073921-148B9551-991F-42BF-BF8C-978F40796DA8

P31

Q35073921-4E9686F7-F827-42B1-8EBA-74DFA6F6EAA5

P356

Q35073921-E84341AC-4465-4593-A95B-7FDC402FE235

P407

Q35073921-A9E5AC68-074C-4EAD-A62F-89D7808D797C

P433

Q35073921-908B57D3-69E7-494B-A6CA-2933D9DF966C

P478

Q35073921-4B5005F2-E1AF-4E22-9350-50FEA524CDB7

P577

Q35073921-A77FF603-6A5F-4588-98D6-E32CBD3E9149

P698

Q35073921-FE054CF4-EF39-4499-9DA9-2C43509A1E08

P932

Q35073921-6E9D4489-0A36-489A-B8F2-4F6A369356F5

P356

S10549-011-1564-5

P1433

Breast Cancer Research and Treatment

P1476

Biologic markers determine both the risk and the timing of recurrence in breast cancer.

@en

P2093

Andrew N J Tutt

http://www.w3.org/2001/XMLSchema#string

Cheryl E Gillett

http://www.w3.org/2001/XMLSchema#string

Christina Yau

http://www.w3.org/2001/XMLSchema#string

Christopher C Benz

http://www.w3.org/2001/XMLSchema#string

Dan H Moore

http://www.w3.org/2001/XMLSchema#string

Elissa Ozanne

http://www.w3.org/2001/XMLSchema#string

Frederick L Baehner

http://www.w3.org/2001/XMLSchema#string

John W Park

http://www.w3.org/2001/XMLSchema#string

Laura J Esserman

http://www.w3.org/2001/XMLSchema#string

Pamela J Tsing

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Gene expression profiling predicts clinical outcome of breast cancer

Molecular portraits of human breast tumours

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Genes that mediate breast cancer metastasis to lung

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

P2888

s10549-011-1564-5

P304

607-616

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-011-1564-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21597921

http://www.w3.org/2001/XMLSchema#string

P932

4324750

http://www.w3.org/2001/XMLSchema#string